Adult-onset Still Disease Market Expected to rise by 2034, Cerecor, Roche, Swedish Orphan Biovitrum, Novartis, Swedish Orphan Biovitrum, AB2 Bio Ltd., expected to drive market expansion | DelveInsight

The Adult-onset Still Disease market growth is driven by factors like increase in the prevalence of Adult-onset Still Disease, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Adult-onset Still Disease market report [https://www.delveinsight.com/report-store/adult-onset-still-disease-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Adult-onset Still Disease market size, share, Adult-onset Still Disease epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Adult-onset Still Disease market size growth forward.

Some of the key highlights from the Adult-onset Still Disease Market Insights Report:

*
As per DelveInsight analysis, the Adult-onset Still Disease market is anticipated to witness growth at a considerable CAGR

*
Several key pharmaceutical companies, including Cerecor, Roche, Swedish Orphan Biovitrum, Novartis, Swedish Orphan Biovitrum, AB2 Bio Ltd., and others, are developing novel products to improve the Adult-onset Still Disease treatment outlook.

*
DelveInsight's epidemiology model estimates that in the US, there were approximately 2,325 diagnosed prevalent cases of AOSD in 2023. This number is expected to increase during the forecast period (2024-2034), driven by greater awareness, improved screening, and advancements in genetic testing.

*
Among the EU4 countries and the UK, Germany had the highest number of diagnosed prevalent cases of AOSD, with about 691 cases in 2023. France followed with approximately 560 cases, and the UK had nearly 550 cases.

*
According to DelveInsight, in 2023, there were approximately 7,464 diagnosed cases of Adult-Onset Still's Disease (AOSD) across the 7 Major Markets (7MM). The United States accounted for about 31% of these cases, while the EU4 and the UK collectively represented around 37%, and Japan accounted for nearly 32%.

*
The AOSD market is expected to grow steadily, with a projected compound annual growth rate (CAGR) of 5% from 2024 to 2034. This growth is driven by the introduction of new therapies, such as Tadekinig Alfa, along with increased awareness, improved diagnosis, and advancements in treatment options.

*
FDA-approved drugs like Canakinumab (Novartis), Anakinra (Swedish Orphan Biopharma), and Tocilizumab (Roche) for AOSD indicate significant market potential, reflecting the growing recognition of AOSD as a distinct therapeutic target.

Strategise your business goals by understanding market dynamics @ Adult-onset Still Disease Market Landscape [https://www.delveinsight.com/report-store/adult-onset-still-disease-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Adult-onset Still Disease Overview

Adult-Onset Still's Disease (AOSD) is a rare systemic inflammatory condition with an unknown cause, leading to significant morbidity. It typically presents with a combination of symptoms such as high fever, a characteristic rash, prolonged joint pain, and systemic issues like sore throat, splenomegaly, hepatomegaly, and lymphadenopathy. While the exact causes are unclear, AOSD may be triggered by environmental factors or infections in individuals genetically predisposed to the condition. Risk factors include a history of autoimmune diseases and age, as AOSD primarily affects adults between their 20s and 40s. The complexity of its diagnosis and the variability of symptoms make treatment and management challenging, underscoring the need for increased awareness and further research.

Do you know the treatment paradigms for different countries? Download our Adult-onset Still Disease Market Sample Report [https://www.delveinsight.com/sample-request/adult-onset-still-disease-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Adult-onset Still Disease Epidemiology Segmentation

DelveInsight's Adult-onset Still Disease market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Adult-onset Still Disease historical patient pools and forecasted Adult-onset Still Disease patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Adult-onset Still Disease Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

*
Adult-onset Still Disease Prevalence

*
Age-Specific Adult-onset Still Disease Prevalence

*
Gender-Specific Adult-onset Still Disease Prevalence

*
Diagnosed and Treatable Cases of Adult-onset Still Disease

Visit for more @ Adult-onset Still Disease Epidemiological Insights [https://www.delveinsight.com/report-store/adult-onset-still-disease-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Adult-onset Still Disease Market Outlook

Adult-Onset Still's Disease (AOSD) is a rare autoinflammatory condition triggered by the innate immune system, causing symptoms like fever, rash, arthritis, sore throat, and liver or spleen involvement. Due to its rarity and lack of large studies, diagnosing AOSD is difficult, and treatment often relies on smaller case reports and clinical experience.

Initial therapy typically involves NSAIDs and corticosteroids, but many patients require escalation to disease-modifying antirheumatic drugs (DMARDs) or biologics if symptoms persist. Biologics targeting inflammatory pathways-such as IL-1 receptor antagonists (e.g., KINERET and ILARIS) and TNF inhibitors-have become important options. In Japan, ACTEMRA (tocilizumab) is approved for cases resistant to other treatments.

New therapies, like Tadekinig alfa (an IL-18 binding protein), have shown early promise but lack sufficient recent data to be included in treatment forecasts. Overall, the AOSD treatment landscape continues to evolve, with research focused on expanding and refining therapeutic strategies.

Adult-onset Still Disease Marketed Drugs

*
ILARIS (canakinumab): NOVARTIS

*
KINERET (anakinra): Swedish Orphan Biovitrum

*
ACTEMRA (tocilizumab): Genentech (ROCHE)

Adult-onset Still Disease Emerging Drugs

*
Tadekinig Alfa: AB2 Bio

Adult-onset Still Disease Key Companies

*
Cerecor

*
Roche

*
Swedish Orphan Biovitrum

*
Novartis

*
Swedish Orphan Biovitrum

*
AB2 Bio Ltd.

*
And others

For more information, visit Adult-onset Still Disease Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/sample-request/adult-onset-still-disease-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Adult-onset Still Disease Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Adult-onset Still Disease, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Adult-onset Still Disease epidemiology in the 7MM

*
Adult-onset Still Disease marketed and emerging therapies

*
Adult-onset Still Disease companies

*
Adult-onset Still Disease market drivers and barriers

Table of Contents:

1 Adult-onset Still Disease Market Key Comprehensive Insights

2 Adult-onset Still Disease Market Report Introduction

3 Competitive Intelligence Analysis for Adult-onset Still Disease

4 Adult-onset Still Disease Market Analysis Overview at a Glance

5 Executive Summary of Adult-onset Still Disease

6 Adult-onset Still Disease Epidemiology and Market Methodology

7 Adult-onset Still Disease Epidemiology and Patient Population

8 Adult-onset Still Disease Patient Journey

9 Adult-onset Still Disease Treatment Algorithm, Adult-onset Still Disease Current Treatment, and Medical Practices

10 Key Endpoints in Adult-onset Still Disease Clinical Trials

11 Adult-onset Still Disease Marketed Therapies

12 Adult-onset Still Disease Emerging Therapies

13 Adult-onset Still Disease: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Adult-onset Still Disease

16 Adult-onset Still Disease Market Key Opinion Leaders Reviews

18 Adult-onset Still Disease Market Drivers

19 Adult-onset Still Disease Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Adult-onset Still Disease Epidemiology 2034

DelveInsight's "Adult-onset Still Disease - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Adult-onset Still Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Adult-onset Still Disease Pipeline 2024

"Adult-onset Still Disease Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Adult-onset Still Disease market. A detailed picture of the Adult-onset Still Disease pipeline landscape is provided, which includes the disease overview and Adult-onset Still Disease treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=adultonset-still-disease-market-expected-to-rise-by-2034-cerecor-roche-swedish-orphan-biovitrum-novartis-swedish-orphan-biovitrum-ab2-bio-ltd-expected-to-drive-market-expansion-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.